Schmid, Peter

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

Bardia, A., Hurvitz, S. A., Tolaney, S. M., Loirat, D., Punie, K., Oliveira, M., Brufsky, A., Sardesai, S. D., Kalinsky, K., Zelnak, A. B., et al. (2021) · New England Journal of Medicine

Breast Cancer Treatment StudiesCancer Treatment and Pharmacology

Cited by 1,711

Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial

Rugo, H. S., Bardia, A., Marmé, F., Cortés, J., Schmid, P., Loirat, D., Trédan, O., Ciruelos, E., Dalenc, F., Gómez Pardo, P., et al. (2023) · The Lancet

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 496

Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study

Schmid, P., Salgado, R., Park, Y. H., Muñoz-Couselo, E., Kim, S. B., Sohn, J., Im, S.-A., Foukakis, T., Kuemmel, S., Dent, R., et al. (2020) · Annals of Oncology

Breast Cancer Treatment StudiesCancer Immunotherapy and Biomarkers

Cited by 413

Biomarkers of depression in cancer patients

Jehn, C. F., Kuehnhardt, D., Bartholomae, A., Pfeiffer, S., Krebs, M., Regierer, A. C., Schmid, P., Possinger, K., & Flath, B. C. (2006) · Cancer

Stress Responses and CortisolTryptophan and brain disorders

Cited by 139

Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): Post-hoc analysis of IMpassion130

Rugo, H. S., Loi, S., Adams, S., Schmid, P., Schneeweiss, A., Barrios, C. H., Iwata, H., Dieras, V. C., Winer, E. P., Kockx, M., et al. (2019) · Annals of Oncology

Cancer Immunotherapy and BiomarkersBreast Cancer Treatment Studies

Cited by 116

Effect of Voluntariness of Participation in Treatment on Short-Term Outcome of Inpatients With Schizophrenia

Steinert, T., & Schmid, P. (2004) · Psychiatric Services

Healthcare Decision-Making and RestraintsSchizophrenia research and treatment

Cited by 44

Abstract P6-11-09: heavily pre-treated breast cancer patients show promising responses in the first in human study of the first-In-class fatty acid synthase (FASN) inhibitor, TVB-2640 in combination with paclitaxel

Brenner, A., Falchook, G., Patel, M., Infante, Jr., Arkenau, H.-T., Dean, E., Borazanci, E., Lopez, J., Moore, K., Schmid, P., et al. (2017) · Cancer Research

Cancer, Lipids, and MetabolismBreast Cancer Treatment Studies

Cited by 19